Interim analysis demonstrated superior progression-free survival with MeziKd versus carfilzomib/dexamethasone in anti-CD38– and lenalidomide-exposed relapsed ...

Gline laid out a catalyst-rich 2026, stating, "The Phase IIb data for mostly is expected firmly in the second half of this year. We now know that because the study is fully enrolled, obviously. Same ...

The Plant Base is the go to B2B news platform for the plant-based food and beverage industry. Refreshment is your ultimate resource for staying informed and up-to-date on the water cooler, vending, ...

When it comes to molding processes in plastics manufacturing, achieving a consistent flow can sometimes feel like trying to steer a ship through rocky waters. The secret to success lies in mastering ...

Unfortunately, the Detroit Tigers were not one of the 12 teams that were taking players in the major league phase of the Rule 5 Draft. Instead, they saw their No. 30 prospect, RJ Petit, get stolen ...

As the premier consumer L1 network, Flow has proven that incubating killer apps is as vital as fostering a robust, open infrastructure. Flow launched its network with groundbreaking partnerships, ...

A potent storm cycle is set to deliver significant snowfall across the Western US through the weekend. While wind issues and fluctuating snow levels present challenges in the PNW and Idaho, the ...

NEW YORK, Dec 4 (Reuters Breakingviews) - Warren Buffett often said that the stock market is a voting machine in the short run, but a weighing machine over longer horizons. The outgoing Berkshire ...

Management expects to request an end of Phase II meeting with the FDA in Q4 2025 to gain alignment on the Phase III program for chronic cough in IPF and to discuss NDA-enabling work. The company is ...

Roche has reported wins for its BTK inhibitor fenebrutinib in a pair of phase 3 studies across two multiple sclerosis (MS) populations. One victory was based on the finding that the candidate was ...

– Single subcutaneous dose of ADX-038 achieved near-complete alternative pathway suppression for 6 months, supporting potent and selective CFB silencing – – Phase 2 studies are ongoing to assess the ...